Cargando…
Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a
The effects of the selective sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin in low dose on cardiac function were investigated in normoglycemic rats. Cardiac parameters were measured by intracardiac catheterization 30 min after intravenous application of empagliflozin to healthy anima...
Autores principales: | Goerg, Jana, Sommerfeld, Manuela, Greiner, Bettina, Lauer, Dilyara, Seckin, Yasemin, Kulikov, Alexander, Ivkin, Dmitry, Kintscher, Ulrich, Okovityi, Sergey, Kaschina, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196699/ https://www.ncbi.nlm.nih.gov/pubmed/34063987 http://dx.doi.org/10.3390/ijms22115437 |
Ejemplares similares
-
SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022) -
Differential Regulation of MMPs, Apoptosis and Cell Proliferation by the Cannabinoid Receptors CB1 and CB2 in Vascular Smooth Muscle Cells and Cardiac Myocytes
por: Greiner, Bettina, et al.
Publicado: (2022) -
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
por: Chen, Sha, et al.
Publicado: (2023) -
Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019) -
SERCA Activity Controls the Systolic Calcium Increase in the Nucleus of Cardiac Myocytes
por: Kiess, Tobias-Oliver, et al.
Publicado: (2019)